Search Results - "BRITTEN, D"

PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types by Britten, Carolyn D.

“…The PI3K/AKT/mTOR and RAS/RAF/MEK/ERK pathways are two of the most frequently dysregulated kinase cascades in human cancer. Molecular alterations in these…”
Get full text

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial by Patel, Manish R, Ellerton, John, Infante, Jeffrey R, Agrawal, Manish, Gordon, Michael, Aljumaily, Raid, Britten, Carolyn D, Dirix, Luc, Lee, Keun-Wook, Taylor, Mathew, Schöffski, Patrick, Wang, Ding, Ravaud, Alain, Gelb, Arnold B, Xiong, Junyuan, Rosen, Galit, Gulley, James L, Apolo, Andrea B

“…The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agents has expanded treatment options for patients with locally advanced or…”
Get full text

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer by Bucher, N, Britten, C D

“…Rigorous quality control steps, termed checkpoints, tightly regulate progression through the cell cycle. DNA-damaging chemotherapy and radiation activate…”
Get full text

Molecular dynamics simulation of aluminium binding to amyloid-β and its effect on peptide structure by Turner, Matthew, Mutter, Shaun T, Kennedy-Britten, Oliver D, Platts, James A

“…Multiple microsecond-length molecular dynamics simulations of complexes of Al(III) with amyloid-β (Aβ) peptides of varying length are reported, employing a…”
Get full text

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer by Mehrotra, Shikhar, Britten, Carolyn D, Chin, Steve, Garrett-Mayer, Elizabeth, Cloud, Colleen A, Li, Mingli, Scurti, Gina, Salem, Mohamed L, Nelson, Michelle H, Thomas, Melanie B, Paulos, Chrystal M, Salazar, Andres M, Nishimura, Michael I, Rubinstein, Mark P, Li, Zihai, Cole, David J

“…Dendritic cells (DCs) enhance the quality of anti-tumor immune response in patients with cancer. Thus, we posit that DC-based immunotherapy, in conjunction…”
Get full text

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies by HIDALGO, Manuel, SIU, Lillian L, FERRANTE, Karen, VON HOFF, Daniel D, SILBERMAN, Sandra, ROWINSKY, Eric K, NEMUNAITIS, John, RIZZO, Jinee, HAMMOND, Lisa A, TAKIMOTO, Chris, ECKHARDT, S. Gail, TOLCHER, Anthony, BRITTEN, Carolyn D, DENIS, Louis

“…To assess the feasibility of administering OSI-774, to recommend a dose on a protracted, continuous daily schedule, to characterize its pharmacokinetic…”
Get full text

The Physiome Model Repository 2 by YU, Tommy, LLOYD, Catherine M, NIELSEN, Poul M. F, NICKERSON, David P, COOLING, Michael T, MILLET, Andrew K, GARNY, Alan, TERKILDSEN, Jonna R, LAWSON, James, BRITTEN, Randall D, HUNTER, Peter J

“…The Physiome Model Repository 2 (PMR2) software was created as part of the IUPS Physiome Project (Hunter and Borg, 2003), and today it serves as the foundation…”
Get full text

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib by Kalous, Ondrej, Conklin, Dylan, Desai, Amrita J, O'Brien, Neil A, Ginther, Charles, Anderson, Lee, Cohen, David J, Britten, Carolyn D, Taylor, Ian, Christensen, James G, Slamon, Dennis J, Finn, Richard S

“…The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies. Trastuzumab and lapatinib are standard…”
Get full text

Redox Signaling and Bioenergetics Influence Lung Cancer Cell Line Sensitivity to the Isoflavone ME-344 by Manevich, Yefim, Reyes, Leticia, Britten, Carolyn D, Townsend, Danyelle M, Tew, Kenneth D

“…ME-344 [(3R,4S)-3,4-bis(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol] is a second-generation derivative natural product isoflavone presently under…”
Get more information

Targeting ErbB receptor signaling: A pan-ErbB approach to cancer by Britten, Carolyn D

“…The ErbB receptors are localized to the cell membrane where they are activated by ligand to trigger a network of signaling pathways. In some cancer cells,…”
Get full text

A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period by Britten, Carolyn D., Kabbinavar, Fairooz, Randolph Hecht, J., Bello, Carlo L., Li, Jim, Baum, Charles, Slamon, Dennis

“…Purpose Sunitinib, an oral multitargeted tyrosine kinase inhibitor that inhibits VEGFR, PDGFR, FLT3, KIT, and RET, is currently approved for the treatment of…”
Get full text

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma by Mita, M.M., Poplin, E., Britten, C.D., Tap, W.D., Rubin, E.H., Scott, B.B., Berk, L., Rivera, V.M., Loewy, J.W., Dodion, P., Haluska, F., Sarantopoulos, J., Mita, A., Tolcher, A.

“…Ridaforolimus is an inhibitor of mTOR with evidence of antitumor activity in an I.V. formulation. This multicenter, open-label, 3 + 3 design nonrandomized,…”
Get full text

Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study by Britten, Carolyn D, Gomes, Antoinette S, Wainberg, Zev A, Elashoff, David, Amado, Rafael, Xin, Yan, Busuttil, Ronald W, Slamon, Dennis J, Finn, Richard S

“…Stimulation of vascular endothelial growth factor (VEGF) has been observed following transarterial chemoembolization (TACE) in hepatocellular cancer (HCC) and…”
Get full text

Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study by Apolo, Andrea B, Infante, Jeffrey R, Balmanoukian, Ani, Patel, Manish R, Wang, Ding, Kelly, Karen, Mega, Anthony E, Britten, Carolyn D, Ravaud, Alain, Mita, Alain C, Safran, Howard, Stinchcombe, Thomas E, Srdanov, Marko, Gelb, Arnold B, Schlichting, Michael, Chin, Kevin, Gulley, James L

“…Purpose We assessed the safety and antitumor activity of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with…”
Get full text

A Phase I Study of Pivaloyloxymethyl Butyrate, a Prodrug of the Differentiating Agent Butyric Acid, in Patients with Advanced Solid Malignancies by PATNAIK, Amita, ROWINSKY, Eric K, ECKHARDT, S. Gail, VILLALONA, Miguel A, HAMMOND, Lisa A, BRITTEN, Carolyn D, SIU, Lillian L, GOETZ, Andrew, FELTON, Sally A, BURTON, Susan, VALONE, Frank H

“…Pivaloyloxymethyl butyrate (AN-9), an acyloxyalkyl ester prodrug of butyric acid (BA), has demonstrated greater potency than BA at inducing malignant cell…”
Get full text

A Phase I and Pharmacological Study of the Farnesyl Protein Transferase Inhibitor L-778,123 in Patients with Solid Malignancies by BRITTEN, Carolyn D, ROWINSKY, Eric K, PEZZULI, Sandy, SPRIGGS, David, SOIGNET, Steven, PATNAIK, Amita, YAO, Siu-Long, DEUTSCH, Paul, YIH LEE, LOBELL, Robert B, MAZINA, Kathryn E, MCCREERY, Heather

“…This Phase I study was performed to assess the feasibility of administering L-778,123, a peptidomimetic farnesyl protein transferase (FPTase) inhibitor, as a…”
Get full text

A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors by Bedard, Philippe L, Tabernero, Josep, Janku, Filip, Wainberg, Zev A, Paz-Ares, Luis, Vansteenkiste, Johan, Van Cutsem, Eric, Pérez-García, José, Stathis, Anastasios, Britten, Carolyn D, Le, Ngocdiep, Carter, Kirsten, Demanse, David, Csonka, Denes, Peters, Malte, Zubel, Angela, Nauwelaerts, Heidi, Sessa, Cristiana

“…MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, and pharmacokinetics of buparlisib (pan class…”
Get full text

Declarative representation of uncertainty in mathematical models by Miller, Andrew K, Britten, Randall D, Nielsen, Poul M F

“…An important aspect of multi-scale modelling is the ability to represent mathematical models in forms that can be exchanged between modellers and tools. While…”
Get full text

A Phase I Study of ABC294640, a First-in-Class Sphingosine Kinase-2 Inhibitor, in Patients with Advanced Solid Tumors by Britten, Carolyn D, Garrett-Mayer, Elizabeth, Chin, Steven H, Shirai, Keisuke, Ogretmen, Besim, Bentz, Tricia A, Brisendine, Alan, Anderton, Kate, Cusack, Susan L, Maines, Lynn W, Zhuang, Yan, Smith, Charles D, Thomas, Melanie B

“…Sphingosine kinases (SK1 and SK2) regulate tumor growth by generating the mitogenic and proinflammatory lipid sphingosine 1-phosphate (S1P). This phase I study…”
Get full text

Development and Validation of a Drug Activity Biomarker that Shows Target Inhibition in Cancer Patients Receiving Enzastaurin, a Novel Protein Kinase C-β Inhibitor by GREEN, Lisa J, MARDER, Philip, ECKHARDT, S. Gail, THORNTON, Donald, RAY, Chad, COOK, Carolyn A, JAKEN, Susan, MUSIB, Luna C, HERBST, Roy S, CARDUCCI, Michael, BRITTEN, Carolyn D, BASCHE, Michele

“…Purpose: To evaluate the effects of the novel protein kinase C (PKC) inhibitor enzastaurin on intracellular phosphoprotein signaling using flow cytometry and…”
Get full text